What it sells
Patient Intelligence Platform for Genetic Disease
Business model breakdown
Buyer: who owns the budget?
Biotech and pharma (small biotech to top-20) paying for patient finding; patients get free or insurance-billed testing.
Trigger: what makes them buy now?
Rare-disease patients are impossible to find for trials and commercialization; patients face a diagnostic odyssey.
Workflow: what inputs become what output?
Patients check eligibility, get free sponsored testing or insurance-billed testing with a genetic counselor; AI/ML/LLMs identify candidates for drug developers within compliant programs.
Economics: what it saves and how it charges
Two-sided: pharma/lab/advocacy partners fund free testing programs and patient discovery; insurance billing for other patients; 200,000+ patients, 50+ advocacy partners.
Distribution: how it reaches customers
Patient advocacy group partnerships, partner sales ('Talk with our team'), online eligibility check.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2019 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.